Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

TROPiCS-02: Sacituzumab Govitecan in HR+/HER2- Breast Cancer

August 24th 2022

A brief review of data from the TROPiCS-02 clinical trial, which evaluated sacituzumab govitecan in HR+/HER2- metastatic or inoperable breast cancer.

DESTINY-Breast04: T-DXd in HER2-Low Metastatic Breast Cancer

August 24th 2022

Expert perspectives on the use of trastuzumab deruxtecan in HER2-low metastatic breast cancer in the context of the DESTINY-Breast04 trial.

EMA Accepts Marketing Authorization Application for Elacestrant in ER+/HER2- Advanced Breast Cancer

August 22nd 2022

The European Medicines Agency has validated a marketing authorization application for elacestrant for estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

Ordering Additional Multigene Assays for Patients with HR+ Breast Cancer

August 19th 2022

Drs Schwartzberg and Pegram debate the value of having patients undergo more than 1 multigene assay to predict their risk of recurrence.

Tools to Guide Treatment Decision-Making in HR+ Breast Cancer

August 19th 2022

Mark Pegram, MD, details the role of biomarkers in predicting recurrences in patients with HR+ breast cancer.

UK’s MHRA Extends Conditional Marketing Authorization for Trastuzumab Deruxtecan to Select HER2+ Metastatic Breast Cancer

August 18th 2022

The United Kingdom Medicines and Healthcare Products Regulatory Agency has extended the conditional marketing authorization of fam-trastuzumab deruxtecan-nxki for single-agent use in adult patients in Great Britain who have HER2-positive unresectable or metastatic breast cancer and have received 1 or more prior HER2-based regimens.

Adverse Event Management With T-DXd in Patients With Breast or Gastric Cancers

August 18th 2022

Contextualizing the use of T-DXd in breast cancer and gastric cancers respectively, panelists highlight optimal management of adverse events in these settings.

Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

August 18th 2022

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

Trastuzumab Deruxtecan Shakes Up Treatment Possibilities for HER2-Low Metastatic Breast Cancer

August 17th 2022

Katherine Tkaczuk, MD, discusses practice-changing data across breast cancer subtypes that were discussed at the 2022 ASCO Annual Meeting, including data from DESTINY-Breast04 and the phase 3 PALOMA-2 trial, plus the utilization of CDK4/6 inhibitors and PARP inhibitors for select patients with breast cancer.

Long-term Data for CDK4/6 Inhibitors Solidify Role in Firstline HR+/HER2- Breast Cancer

August 17th 2022

CDK4/6 inhibitors have carved out a substantial role in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer.

HER2CLIMB: Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

August 17th 2022

Focusing on the HER2CLIMB trial in HER2+ metastatic breast cancer, expert oncologists consider the value of a tucatinib-based regimen in this setting.

DESTINY-Breast03: T-DXd in Previously Treated HER2+ Breast Cancer

August 17th 2022

Comprehensive discussion on the DESTINY-Breast03 clinical trial evaluating trastuzumab deruxtecan in patients with previously treated HER2+ metastatic breast cancer.

Liquid Biopsy Assay Expands Offerings to Include MRD, Disease Recurrence Detection in Early-Stage Breast and Lung Cancer

August 16th 2022

The Guardant Reveal assay has been expanded for the detection of minimal residual disease and disease recurrence in patients with early-stage breast cancer and lung cancer.

Sacituzumab Govitecan Prolongs OS in Heavily Pretreated HR+ Breast Cancer

August 15th 2022

Sacituzumab govitecan elicited a statistically significant and clinically meaningful improvement in overall survival vs standard chemotherapy in patients with hormone receptor–positive, HER2-negative breast cancer who received prior treatment with endocrine therapy, CDK4/6 inhibitors, and 2 to 4 lines of chemotherapy, according to findings from the second interim analysis of the phase 3 TROPiCS-02 trial.

Trastuzumab Deruxtecan Improves PFS, OS in T-DM1–Pretreated HER2+ Metastatic Breast Cancer

August 15th 2022

Trastuzumab deruxtecan led to a statistically significant improvement in progression-free survival and overall survival vs treatment with physician’s choice in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Future Directions in Care for HER2+ Breast Cancer

August 15th 2022

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

Interpreting Clinical Trial Data in the Setting of HER2-Low Breast Cancer

August 15th 2022

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.